acy3.2 Antibody

What is ACY3 protein and what cellular functions does it perform?

ACY3, also known as Aminoacylase-3, is an enzyme with a molecular mass of approximately 36 kDa that plays an important role in deacetylating mercapturic acids in kidney proximal tubules. It also acts on N-acetyl-aromatic amino acids . The protein is also known by several alternative names including ASPA2, Acylase III, Aspartoacylase-2, Hepatitis C virus core-binding protein 1 (HCBP1), and N-acyl-aromatic-L-amino acid amidohydrolase . Understanding this protein's function is essential for researchers investigating kidney metabolism, detoxification pathways, and potentially its role in disease states.

What biological samples can be analyzed with ACY3 antibodies?

Based on validated research data, ACY3 antibodies have demonstrated reactivity with both human and mouse samples . The antibodies can detect endogenous levels of total ACY3 protein in these species, making them suitable for comparative studies. Researchers should note that while these species have been validated, other species may work based on sequence homology, but would require additional validation by the researcher.

What experimental applications are ACY3 antibodies validated for?

ACY3 antibodies have been validated for:

These applications allow researchers to detect and quantify ACY3 protein expression in tissue lysates and examine its distribution in fixed tissue sections .

How should I optimize Western blotting protocols for ACY3 detection?

For optimal Western blot results with ACY3 antibodies, follow these methodological recommendations:

• Sample preparation: Use fresh tissue lysates (kidney tissues show high expression) with approximately 40 μg of protein per lane .

• Gel selection: 10% SDS-PAGE gels are appropriate for resolving the 35-36 kDa ACY3 protein .

• Antibody dilution: Use primary anti-ACY3 antibody at 1/500 dilution for optimal signal-to-noise ratio .

• Secondary antibody: Apply HRP-conjugated secondary antibodies at 1/8000 dilution .

• Exposure time: Short exposure times (~5 seconds) are typically sufficient to visualize bands .

• Expected band: Look for a band at approximately 35 kDa, which corresponds to the predicted molecular weight of ACY3 .

For troubleshooting, consider titrating antibody concentrations if signal strength is suboptimal or if background is excessive.

What methodology produces optimal results for ACY3 immunohistochemistry?

For IHC-P applications using ACY3 antibodies, implement the following protocol:

• Tissue preparation: Use paraffin-embedded tissue sections (human cervical cancer tissue has shown good results) .

• Antigen retrieval: Perform heat-induced epitope retrieval in citrate buffer (pH 6.0).

• Antibody dilution: Use a 1/25 dilution of ACY3 antibody for optimal staining .

• Detection system: Use an HRP-polymer detection system followed by DAB visualization.

• Counterstaining: Hematoxylin counterstaining will help visualize tissue architecture.

Researchers should include appropriate positive tissues (such as kidney) and negative controls (primary antibody omission) for experimental validation.

How can I validate the specificity of my ACY3 antibody results?

To ensure the specificity of ACY3 antibody detection, implement these validation approaches:

• Knockout/knockdown controls: Use ACE2 siRNA knockdown methodology similar to that described for other proteins in the search results . This approach can be adapted for ACY3 by transfecting cells with ACY3-specific siRNA and comparing antibody detection in knockdown versus control cells.

• Peptide competition assay: Pre-incubate the antibody with immunizing peptide before application to samples; specific binding should be blocked.

• Multiple antibody verification: Use antibodies from different sources or those targeting different epitopes to confirm consistent detection patterns.

• Positive and negative tissue controls: Include known positive tissues (kidney) and tissues with low/no expression.

What controls should be included when using ACY3 antibodies?

A comprehensive experimental design with ACY3 antibodies should include:

These controls will help researchers distinguish between true positive results and experimental artifacts.

How should ACY3 antibodies be properly stored and handled to maintain activity?

For optimal antibody performance, follow these storage and handling guidelines:

• Long-term storage: Store antibody at -20°C in the provided formulation (typically containing glycerol and preservative) .

• Working solution: Aliquot to avoid repeated freeze-thaw cycles, which can degrade antibody activity.

• Formulation considerations: Note that the antibody is typically supplied in PBS (pH 7.3) with 0.05% NaN3 and 50% glycerol .

• Stability: When properly stored, antibodies should maintain activity until the expiration date.

• Transportation: Transport on ice or with cold packs to maintain antibody integrity.

Improper storage can lead to reduced antibody sensitivity and specificity, compromising experimental outcomes.

How do I interpret Western blot results with ACY3 antibodies?

When analyzing ACY3 Western blot data:

• Band size verification: Confirm that the observed band appears at the expected 35 kDa position .

• Tissue expression pattern: Expect strong expression in kidney tissue, which serves as a positive control .

• Signal intensity assessment: Evaluate relative expression levels by comparing to housekeeping protein controls.

• Multiple bands interpretation: Additional bands may represent post-translational modifications, splice variants, or non-specific binding.

• Quantification approach: For quantitative analysis, normalize ACY3 band intensity to loading control (β-actin) using imaging software similar to ImageStudio mentioned in the methodology .

Inconsistent results may indicate issues with sample preparation, antibody quality, or protocol execution.

What are common technical issues when using ACY3 antibodies and how can they be resolved?

When troubleshooting, change only one parameter at a time to identify the source of the problem.

How can ACY3 antibodies be adapted for flow cytometry applications?

While the search results don't specifically mention flow cytometry validation for ACY3 antibodies, researchers can adapt them for this application following these methodological approaches:

• Cell preparation: Use single-cell suspensions from tissues known to express ACY3 or transfected cell lines.

• Fixation and permeabilization: Since ACY3 is an intracellular protein, use appropriate fixation (4% paraformaldehyde) and permeabilization (0.1% Triton X-100 or commercial permeabilization buffers).

• Antibody titration: Test a range of primary antibody concentrations (starting with 1:100-1:500 dilutions).

• Secondary detection: Use fluorophore-conjugated secondary antibodies appropriate for your cytometer configuration.

• Controls: Include unstained cells, secondary-only controls, and ideally ACY3-knockdown cells as a negative control.

The flow cytometry protocols described for FcγR detection in the search results provide a general methodology that can be adapted .

What considerations are important when designing experiments to study ACY3 in disease models?

When investigating ACY3 in disease contexts:

• Expression analysis: Quantify ACY3 expression levels in normal versus diseased tissues using Western blot (1/500 dilution) or IHC-P (1/25 dilution) .

• Functional studies: Consider knockdown approaches using siRNA methodology similar to that described for ACE2 .

• Tissue selection: Focus on kidney tissue where ACY3 plays important roles in deacetylating mercapturic acids .

• Co-expression studies: Investigate relationships with other proteins in metabolic pathways using co-immunoprecipitation or co-localization studies.

• Inter-species comparisons: Leverage the antibody's cross-reactivity with mouse and human samples for translational research .

Careful experimental design accounting for these factors will enhance the validity and impact of ACY3-focused disease research.